Gene expression profiling and pathway analysis identify the integrin signaling pathway to be altered by IL-1β in human pancreatic cancer cells: Role of JNK

Cancer Letters

Volumn 320, Issue 1, 2012, Pages 86-95

  Verma, Gaurav ^a   Bhatia, Himanshi ^a   Datta, Malabika ^a  

^a CSIR INSTITUTE OF GENOMICS AND INTEGRATIVE BIOLOGY   (India)

Author keywords

Integrin signaling; Interleukin 1 ; JNK; Microarray; Pancreas

Indexed keywords

ALPHA5 INTEGRIN; CELL PROTEIN; INTEGRIN; INTERLEUKIN 1BETA; SMALL INTERFERING RNA; STRESS ACTIVATED PROTEIN KINASE; VINCULIN;

ARTICLE; CANCER CELL; CELL CYCLE; CELL MIGRATION; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; MITOSIS; PANCREAS CANCER; PRIORITY JOURNAL; UPREGULATION; WOUND HEALING;

CELL LINE, TUMOR; DOWN-REGULATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTEGRIN ALPHA5; INTERLEUKIN-1BETA; MAP KINASE KINASE 4; PANCREATIC NEOPLASMS; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; UP-REGULATION; VINCULIN;

AGOUTI PACA;

EID: 84859218898     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.01.036     Document Type: Article

References (74)

1. Bunt S.K., Sinha P., Clements V.K., Leips J., Ostrand-Rosenberg S. Inflammation induces myeloid-derived suppressor cells that facilitate tumor progression. J. Immunol. 2006, 176:284-290.
2. Algul H., Treiber M., Lesina M., Schmid R.M. Mechanisms of disease: chronic inflammation and cancer in the pancreas-a potential role for pancreatic stellate cells?. Nat. Clin. Pract. Gastroenterol. Hepatol. 2007, 4:454-462.
3. Wraith D.C. Anti-cytokine vaccines and the immunotherapy of autoimmune diseases. Eur J. Immunol. 2006, 36:2844-2848.
4. Apte R.N., Dotan S., Elkabets M., White M.R., Reich E., Carmi Y., Song X., Dvozkin T., Krelin Y., Voronov E. The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions. Cancer Metastasis Rev. 2006, 25:387-408.
5. Maedler K., Sergeev P., Ris F., Oberholzer J., Joller-Jemelka H.I., Spinas G.A., Kaiser N., Halban P.A., Donath M.Y. Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets. J. Clin. Invest. 2002, 110:851-860.
6. Guo Z., Zhang M., An H., Chen W., Liu S., Guo J., Yu Y., Cao X. Fas ligation induces IL-1beta-dependent maturation and IL-1beta-independent survival of dendritic cells: different roles of ERK and NF-kappaB signaling pathways. Blood 2003, 102:4441-4447.
7. Li X., Commane M., Jiang Z., Stark GR. IL-1-induced NFkappa B and c-Jun N-terminal kinase (JNK) activation diverge at IL-1 receptor-associated kinase (IRAK). Proc. Natl. Acad. Sci. USA 2001, 98:4461-4465.
8. Chambers K.T., Unverferth J.A., Weber S.M., Wek R.C., Urano F., Corbett J.A. The role of nitric oxide and the unfolded protein response in cytokine-induced beta-cell death. Diabetes 2008, 57:124-132.
9. Arlt A., Vorndamm J., Muerkoster S., Yu H., Schmidt W.E., Fölsch U.R., Schäfer H. Autocrine production of interleukin 1beta confers constitutive nuclear factor kappaB activity and chemoresistance in pancreatic carcinoma cell lines. Cancer Res. 2002, 62:910-916.
10. Angst E., Reber H.A., Hines O.J., Eibl G. Mononuclear cell-derived interleukin-1 beta confers chemoresistance in pancreatic cancer cells by upregulation of cyclooxygenase-2. Surgery 2008, 144:57-65.
11. Muerkoster S.S., Lust J., Arlt A., Häsler R., Witt M., Sebens T., Schreiber S., Fölsch U.R., Schäfer H. Acquired chemoresistance in pancreatic carcinoma cells: induced secretion of IL-1beta and NO lead to inactivation of caspases. Oncogene 2006, 25:3973-3981.
12. Greco E., Basso D., Fogar P., Mazza S., Navaglia F., Zambon C.F., Falda A., Pedrazzoli S., Ancona E., Plebani M. Pancreatic cancer cells invasiveness is mainly affected by interleukin-1beta not by transforming growth factor-beta1. Int. J. Biol. Markers 2005, 20:235-241.
13. Stefani A.L., Basso D., Panozzo M.P., Greco E., Mazza S., Zancanaro F., De Franchis G., Plebani M. Cytokines modulate MIA PaCa 2 and CAPAN-1 adhesion to extracellular matrix proteins. Pancreas 1999, 19:362-369.
14. Storling J., Zaitsev S.V., Kapelioukh I.L., Karlsen A.E., Billestrup N., Berggren P.O., Mandrup-Poulsen T. Calcium has a permissive role in interleukin-1beta-induced c-jun N-terminal kinase activation in insulin-secreting cells. Endocrinology 2005, 146:3026-3036.
15. Wang Q., Zhang H., Zhao B., Fei H. IL-1beta caused pancreatic beta-cells apoptosis is mediated in part by endoplasmic reticulum stress via the induction of endoplasmic reticulum Ca2+ release through the c-Jun N-terminal kinase pathway. Mol. Cell. Biochem. 2009, 324:183-190.
16. 2-terminal kinase activity in insulin-secreting cells: evidence for cytoplasmic restriction. Diabetes 2001, 50:2721-2728.
17. Storling J., Binzer J., Andersson A.K., Züllig R.A., Tonnesen M., Lehmann R., Spinas G.A., Sandler S., Billestrup N., Mandrup-Poulsen T. Nitric oxide contributes to cytokine-induced apoptosis in pancreatic beta cells via potentiation of JNK activity and inhibition of Akt. Diabetologia 2005, 48:2039-2050.
18. Bonny C., Oberson A., Negri S., Sauser C., Schorderet D.F. Cell-permeable peptide inhibitors of JNK: novel blockers of beta-cell death. Diabetes 2001, 50:77-82.
19. Verma G., Datta M. IL-1beta induces ER stress in a JNK dependent manner that determines cell death in human pancreatic epithelial MIA PaCa-2 cells. Apoptosis 2010, 15:864-876.
20. Pfaffl M.W. A new mathematical model for relative quantification in Real-Time RT-PCR. Nucl. Acids. Res. 2001, 29:e45.
21. Org T., Rebane A., Kisand K., Laan M., Haljasorg U., Andreson R., Peterson P. AIRE activated tissue specific genes have histone modifications associated with inactive chromatin. Hum. Mol. Genet. 2009, 18:4699-4710.
22. Kreydiyyeh S.I., Haddad J.J., Garabedian B.S. Interleukin-1 beta inhibits the intestinal transport of [14C] 3-O-methylglucose in the rat. Life Sci. 1998, 63:1913-1919.
23. + absorption and stimulate anion secretion by IMCD cells. Am. J. Physiol. 1998, 275:F946-F954.
24. Prow N.A., Irani D.N. The inflammatory cytokine, interleukin-1 beta, mediates loss of astroglial glutamate transport and drives excitotoxic motor neuron injury in the spinal cord during acute viral encephalomyelitis. J. Neurochem. 2008, 105:1276-1286.
25. Homaidan F.R., Desai H., Zhao L., Broutman G., Burakoff R. Regulation of electrolyte transport with IL-1beta in rabbit distal colon. Mediator. Inflamm. 1995, 4:61-66.
26. Sugiyama T., Sadzuka Y., Tanaka K., Sonobe T. Inhibition of glutamate transporter by theanine enhances the therapeutic efficacy of doxorubicin. Toxicol. Lett. 2001, 121:89-96.
27. Huang Y., Dai Z., Barbacioru C., Sadee W. Cystine-glutamate transporter SLC7A11 in cancer chemosensitivity and chemoresistance. Cancer. Res. 2005, 65:7446-7454.
28. Ye Z.C., Rothstein J.D., Sontheimer H. Compromised glutamate transport in human glioma cells: reduction-mislocalization of sodium-dependent glutamate transporters and enhanced activity of cystine-glutamate exchange. J. Neurosci. 1999, 19:10767-10777.
29. White M.K., Bramwell M.E., Harris H. Hexose transport in hybrids between malignant and normal cells. Nature 1981, 294:232-235.
30. Ganter M.T., Roux J., Miyazawa B., Howard M., Frank J.A., Su G., Sheppard D., Violette S.M., Weinreb P.H., Horan G.S., Matthay M.A., Pittet J.F. Interleukin-1beta causes acute lung injury via alphavbeta5 and alphavbeta6 integrin-dependent mechanisms. Circ. Res. 2008, 102:804-812.
31. Björkqvist M., Wild E.J., Thiele J., Silvestroni A., Andre R., Lahiri N., Raibon E., Lee R.V., Benn C.L., Soulet D., Magnusson A., Woodman B., Landles C., Pouladi M.A., Hayden M.R., Khalili-Shirazi A., Lowdell M.W., Brundin P., Bates G.P., Leavitt B.R., Möller T., Tabrizi S.J. A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease. J. Exp. Med. 2008, 205:1869-1877.
32. Ona V.O., Li M., Vonsattel J.P.G., Andrews L.J., Khan S.Q., Chung W.M., Frey A.S., Menon A.S., Li X.J., Stieg P.E., Yuank J., Penney J.B., Young A.B., Cha J.J., Friedlander R.M. Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease. Nature 1999, 399:263-267.
33. Apostol B.L., Illes K., Pallos J., Bodai L., Wu J., Strand A., Schweitzer E.S., Olson J.M., Kazantsev A., Marsh J.L., Thompson L.M. Mutant huntingtin alters MAPK signaling pathways in PC12 and striatal cells: ERK1/2 protects against mutant huntingtin-associated toxicity. Hum. Mol. Genet. 2006, 15:273-285.
34. Huang S.S., He J., Zhao D.M., Xu X.Y., Tan H.P., Li H. Effects of mutant huntingtin on mGluR5-mediated dual signaling pathways: implications for therapeutic interventions. Cell Mol. Neurobiol. 2010, 30:1107-1115.
35. Meriin A.B., Sherman M.Y. Role of molecular chaperones in neurodegenerative disorders. Int. J. Hyperthermia 2005, 21:403-419.
36. Perrin V., Dufour N., Raoul C., Hassig R., Brouillet E., Aebischer P., Luthi-Carter R., Deglon N. Implication of the JNK pathway in a rat model of Huntington's disease. Exp. Neurol. 2009, 215:191-200.
37. Reinhart P.H., Kaltenbach L.S., Essrich C., Dunn D.E., Eudailey J.A., DeMarco C.T., Turmel G.J., Whaley J.C., Wood A., Cho S., Lo D.C. Identification of anti-inflammatory targets for Huntington's disease using a brain slice-based screening assay. Neurobiol. Dis. 2011, 43:248-256.
38. Sze W.M., Lee A.W., Yau T.K., Yeung R.M., Lau K.Y., Leung S.K., Hung A.W., Lee M.C., Chappell R., Chan K. Primary tumor volume of nasopharyngeal carcinoma: prognostic significance for local control. Int. J. Radiat. Oncol. Biol. Phys. 2004, 59:21-27.
39. Turner N., Grose R. Fibroblast growth factor signaling: from development to cancer. Nat. Rev. Cancer. 2010, 10:116-129.
40. Schwertfeger K.L. Fibroblast growth factors in development and cancer: insights from the mammary and prostate glands. Curr. Drug. Targets. 2009, 10:632-644.
41. Vestergaard J., Bak M., Larsen L.A. The hedgehog signaling pathway in cancer. Prog. Mol. Subcell. Biol. 2005, 40:1-28.
42. Pasca di M.M., Hebrok M. Hedgehog signaling in cancer formation and maintenance. Nat. Rev. Cancer. 2003, 3:903-911.
43. Toftgard R. Hedgehog signaling in cancer. Cell. Mol. Life. Sci. 2000, 57:1720-1731.
44. Holroyde C.P., Reichard G.A. Carbohydrate metabolism in cancer cachexia. Cancer. Treat. Rep. 1981, 65(Suppl 5):55-59.
45. Martin K.H., Slack J.K., Boerner S.A., Martin C.C., Parsons J.T. Integrin connections map: to infinity and beyond. Science 2002, 296:1652-1653.
46. Weber G. Ordered biochemical program of gene expression in cancer cells. Biochemistry (Mosc) 2001, 66:1164-1173.
47. Stender S., Astrup A., Dyerberg J. Ruminant and industrially produced trans fatty acids: health aspects. Food. Nutr. Res. 2008, 52:10.
48. Havrylov S., Redowicz M.J., Buchman V.L. Emerging roles of Ruk/CIN85 in vesicle-mediated transport, adhesion, migration and malignancy. Traffic 2010, 11:721-731.
49. Park C., Kim J.R., Shim J.K., Kang B.S., Park Y.G., Nam K.S., Lee Y.C., Kim C.H. Inhibitory effects of streptozotocin, tumor necrosis factor-alpha, and interleukin-1beta on glucokinase activity in pancreatic islets and gene expression of GLUT2 and glucokinase. Arch. Biochem. Biophys. 1999, 362:217-224.
50. Le V.M., Gripon P., Stieger B., Fardel O. Down-regulation of organic anion transporter expression in human hepatocytes exposed to the proinflammatory cytokine interleukin 1beta. Drug. Metab. Dispos. 2008, 36:217-222.
51. Eisenhut M. Changes in ion transport in inflammatory disease. J. Inflamm. 2006, 3:5.
52. Fogal B., Li J., Lobner D., McCullough L.D., Hewett S.J. System x(c)- activity and astrocytes are necessary for interleukin-1 beta-mediated hypoxic neuronal injury. J. Neurosci. 2007, 27:10094-10105.
53. Schwartz M.A., Ginsberg M.H. Networks and crosstalk: integrin signaling spreads. Nat. Cell. Biol 2002, 4:E65-E68.
54. Sawai H., Funahashi H., Matsuo Y., Yamamoto M., Okada Y., Hayakawa T., Manabe T. Expression and prognostic roles of integrins and interleukin-1 receptor type I in patients with ductal adenocarcinoma of the pancreas. Dig. Dis. Sci. 2003, 48:1241-1250.
55. Desgrosellier J.S., Cheresh D.A. Integrins in cancer: biological implications and therapeutic opportunities. Nat. Rev. Cancer. 2010, 10:9-22.
56. Van W.C., Kozarsky K.F., Warren A.B., Kidd L., Paugh D., Liebert M., Carey T.E. The A9 antigen associated with aggressive human squamous carcinoma is structurally and functionally similar to the newly defined integrin alpha 6 beta 4. Cancer. Res. 1991, 51:2395-2402.
57. Liebert M., Washington R., Wedemeyer G., Carey T.E., Grossman H.B. Loss of co-localization of alpha 6 beta 4 integrin and collagen VII in bladder cancer. Am. J. Pathol. 1994, 144:787-795.
58. Bonkhoff H., Stein U., Remberger K. Differential expression of alpha 6 and alpha 2 very late antigen integrins in the normal, hyperplastic, and neoplastic prostate: simultaneous demonstration of cell surface receptors and their extracellular ligands. Hum. Pathol. 1993, 24:243-248.
59. Rabinovitz I., Nagle R.B., Cress A.E. Integrin alpha 6 expression in human prostate carcinoma cells is associated with a migratory and invasive phenotype in vitro and in vivo. Clin. Exp. Metastasis. 1995, 13:481-491.
60. Pignatelli M., Hanby A.M., Stamp G.W. Low expression of beta 1, alpha 2 and alpha 3 subunits of VLA integrins in malignant mammary tumours. J. Pathol. 1991, 165:25-32.
61. Zutter M.M., Mazoujian G., Santoro S.A. Decreased expression of integrin adhesive protein receptors in adenocarcinoma of the breast. Am. J. Pathol. 1990, 137:863-870.
62. Rodriguez Fernandez J.L., Geiger B., Salomon D., Sabanay I., Zoller M., Ben-Ze'ev A. Suppression of tumorigenicity in transformed cells after transfection with vinculin cDNA. J. Cell. Biol. 1992, 119:427-438.
63. Glukhova M., Koteliansky V., Sastre X., Thiery J.P. Adhesion systems in normal breast and in invasive breast carcinoma. Am. J. Pathol. 1995, 146:706-716.
64. Subauste M.C., Nalbant P., Adamson E.D., Hahn K.M. Vinculin controls PTEN protein level by maintaining the interaction of the adherens junction protein beta-catenin with the scaffolding protein MAGI-2. J. Biol. Chem. 2005, 280:5676-5681.
65. Subauste M.C., Pertz O., Adamson E.D., Turner C.E., Junger S., Hahn K.M. Vinculin modulation of paxillin-FAK interactionsregulates ERK to control survival and motility. J. Cell. Biol. 2004, 165:371-381.
66. Jones J., Berkhoff S., Weich E., Engl T., Wedel S., Relja B., Jonas D., Blaheta R.A. Transient down-regulation of beta1 integrin subtypes on kidney carcinoma cells is induced by mechanical contact with endothelial cell membranes. J. Cell. Mol. Med. 2007, 11:826-838.
67. Winkler A.K., Liu Z., Bruns-henne D., Kornmann M. The c-Jun N-terminal kinase inhibitor SP600125 inhibits pancreatic cancer cell growth. Ger. Surg. Soc. 2006, 35:151-153.
68. Liu W., Reinmuth N., Stoeltzing O., Parikh A.A., Tellez C., Williams S., Jung Y.D., Fan F., Takeda A., Akagi M., Bar-Eli M., Gallick G.E., Ellis L.M. Cyclooxygenase-2 is up-regulated by interleukin-1 beta in human colorectal cancer cells via multiple signaling pathways. Cancer Res. 2003, 63:3632-3636.
69. Cheng C.Y., Hsieh H.L., Sun C.C., Lin C.C., Luo S.F., Yang C.M. IL-1 beta induces urokinase-plasminogen activator expression and cell migration through PKC alpha, JNK1/2, and NF-kappaB in A549 cells. J. Cell Physiol. 2009, 219:183-193.
70. Lin C.C., Kuo C.T., Cheng C.Y., Wu C.Y., Lee C.W., Hsieh H.L., Lee I.T., Yang C.M. IL-1 beta promotes A549 cell migration via MAPKs/AP-1- and NF-kappaB-dependent matrix metalloproteinase-9 expression. Cell Signal. 2009, 21:1652-1662.
71. Aggarwal B.B., Shishodia S., Sandur S.K., Pandey M.K., Sethi G. Inflammation and cancer: how hot is the link?. Biochem. Pharmacol. 2006, 72:1605-1621.
72. Potapova O., Gorospe M., Bost F., Dean N.M., Gaarde W.A., Mercola D., Holbrook N.J. c-Jun N-terminal kinase is essential for growth of human T98G glioblastoma cells. J. Biol. Chem. 2000, 275:24767-24775.
73. Huang C., Jacobson K., Schaller M.D. A role for JNK-paxillin signaling in cell migration. Cell Cycle 2004, 3:4-6.
74. Huang C., Jacobson K., Schaller M.D. MAP kinases and cell migration. J. Cell Sci. 2004, 117:4619-4628.